Cargando…

Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug

Amphetamine-Dextroamphetamine-induced cardiomyopathy has become an emerging cause of heart failure in teenage and young adult populations. With its increasingly widespread use for the treatment of attention-deficit/hyperactivity disorder (ADHD) as well as misuse as a “study drug” to increase concent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewars, Jennaire T, Wiarda, Karen P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368484/
https://www.ncbi.nlm.nih.gov/pubmed/37496550
http://dx.doi.org/10.7759/cureus.40942
_version_ 1785077515141775360
author Lewars, Jennaire T
Wiarda, Karen P
author_facet Lewars, Jennaire T
Wiarda, Karen P
author_sort Lewars, Jennaire T
collection PubMed
description Amphetamine-Dextroamphetamine-induced cardiomyopathy has become an emerging cause of heart failure in teenage and young adult populations. With its increasingly widespread use for the treatment of attention-deficit/hyperactivity disorder (ADHD) as well as misuse as a “study drug” to increase concentration for educational performance, more patients are at risk of this cardiac manifestation, especially those without knowledge of these risks. It becomes vital to highlight the correlation of amphetamine-dextroamphetamine use and heart failure in order to increase awareness of this condition. This case study highlights the manifestation of tachycardia-induced cardiomyopathy in a 38-year-old female patient with long-standing amphetamine-dextroamphetamine use for refractory narcolepsy. Our patient was evaluated utilizing a thyroid panel, lipid profiles, EKG, Holter monitoring, stress echocardiography, and left heart catheterization, revealing an unremarkable thyroid panel, a left ventricular ejection fraction (LVEF) of 20-25% from 35% to 40% and normal coronary vessels. Amphetamine-dextroamphetamine was discontinued with the introduction of metoprolol, aspirin, and atorvastatin. The mainstay of treatment includes cessation of amphetamine-dextroamphetamine. It is important that physicians continue to recognize the implication of amphetamine-dextroamphetamine in the diagnosis of non-ischemic cardiomyopathy in young patients presenting with heart failure like symptomology and to attain a comprehensive history in order to establish this diagnosis. 
format Online
Article
Text
id pubmed-10368484
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103684842023-07-26 Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug Lewars, Jennaire T Wiarda, Karen P Cureus Cardiology Amphetamine-Dextroamphetamine-induced cardiomyopathy has become an emerging cause of heart failure in teenage and young adult populations. With its increasingly widespread use for the treatment of attention-deficit/hyperactivity disorder (ADHD) as well as misuse as a “study drug” to increase concentration for educational performance, more patients are at risk of this cardiac manifestation, especially those without knowledge of these risks. It becomes vital to highlight the correlation of amphetamine-dextroamphetamine use and heart failure in order to increase awareness of this condition. This case study highlights the manifestation of tachycardia-induced cardiomyopathy in a 38-year-old female patient with long-standing amphetamine-dextroamphetamine use for refractory narcolepsy. Our patient was evaluated utilizing a thyroid panel, lipid profiles, EKG, Holter monitoring, stress echocardiography, and left heart catheterization, revealing an unremarkable thyroid panel, a left ventricular ejection fraction (LVEF) of 20-25% from 35% to 40% and normal coronary vessels. Amphetamine-dextroamphetamine was discontinued with the introduction of metoprolol, aspirin, and atorvastatin. The mainstay of treatment includes cessation of amphetamine-dextroamphetamine. It is important that physicians continue to recognize the implication of amphetamine-dextroamphetamine in the diagnosis of non-ischemic cardiomyopathy in young patients presenting with heart failure like symptomology and to attain a comprehensive history in order to establish this diagnosis.  Cureus 2023-06-25 /pmc/articles/PMC10368484/ /pubmed/37496550 http://dx.doi.org/10.7759/cureus.40942 Text en Copyright © 2023, Lewars et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Lewars, Jennaire T
Wiarda, Karen P
Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug
title Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug
title_full Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug
title_fullStr Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug
title_full_unstemmed Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug
title_short Amphetamine-Dextroamphetamine-Induced Cardiomyopathy, an Emerging Cause of Heart Failure in Young Patient Populations: A Case Study Involving the Study Drug
title_sort amphetamine-dextroamphetamine-induced cardiomyopathy, an emerging cause of heart failure in young patient populations: a case study involving the study drug
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368484/
https://www.ncbi.nlm.nih.gov/pubmed/37496550
http://dx.doi.org/10.7759/cureus.40942
work_keys_str_mv AT lewarsjennairet amphetaminedextroamphetamineinducedcardiomyopathyanemergingcauseofheartfailureinyoungpatientpopulationsacasestudyinvolvingthestudydrug
AT wiardakarenp amphetaminedextroamphetamineinducedcardiomyopathyanemergingcauseofheartfailureinyoungpatientpopulationsacasestudyinvolvingthestudydrug